Next-Generation Combination Therapy In Oncology
Executive Summary
Despite significant scientific advances tied to the molecular understanding of cancer, clinical advances have been more limited, largely because the complexity of most tumors defies novel single-target approaches. Clinical advances in the future will require developing rational combinations of targeted therapeutics, as well as leveraging advances in biomarkers and clinical trial design. Vetting new targets with a biomarker, pursuing them in combination trials with several targeted agents, and efficiently moving the resulting rational combination through development to regulatory approval will be the roadmap for commercial success.
You may also be interested in...
Biopharma In 2011: A Year Of Transition
If 2010 was the year when pharma introduced new models, 2011 was the year it discovered that executing on its plans required a new mindset. There was a realization that pharma input and capital were required at the earliest stages of company creation. Innovation remained the order of the day, though pharma’s attempts to innovate looked strikingly similar to one another. We continued to see risk-sharing deal structures, emphasis on emerging markets, ongoing externalization and the biotech-ification of pharma, and stronger emphasis on “unmet medical need. Pharma also did more to work with VCs, payors, generics companies, and each other. The year saw a recovery in US drug approvals and launches, but the high prices associated with some of those new therapies and austerity in Europe also shed light on the health technology assessment-dominated future that likely faces most markets, including the US.
Front-Line Of Melanoma Market Could Be Marketing Battle
Roche's vemurafenib and Bristol-Myers Squibb's Yervoy (ipilimumab) are most likely synergistic treatments for metastatic melanoma that can be used in combination or sequentially. But in certain front-line patients, there could be a struggle between the two different therapeutic options.
What New Cancer Pathway Programs Mean For The Drug Industry
New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.